Ann: Results of Meeting, page-4

in a hypothetical scenario based on my modelling after share consolidation PH wants another mansion and decides to do CR, we will have to do another 27 raises based on previous CR by Imugene we will be raising another 2+ billion dollars to get to 7 billion float again.. now the modelling , this is just for modelling purposes, please evaluate yourself.. not an investment advice

Drug	Stage by 2030	Commercial Status	Funding Source
Azer-cel	Phase 3 or Filed	Possibly partnered or acquired	Self-funded + CR + Partner
onCARlytics	Mid–Late Phase 2	Potential licensing deal	CR + Pharma JV
VAXINIA	Phase 3	Partnered or acquired	CR + external licensing
HER-Vaxx	Out-licensed	Low revenue or dormant	Partner only
PD1-Vaxx	Dormant or sold	Low or nil	Partner only
aCF33 Virus	Phase 1 start	Early pipeline expansion	CR-based support

Pipeline Bucket	Estimated Allocation (AUD)	% of Total CR	Rationale
Azer-cel (Ph2 + Ph3)	~A$900M	~42%	Cell therapy trials are very expensive
onCARlytics	~A$400M	~19%	Dual-platform (virus + cell therapy)
VAXINIA (CF33-hNIS)	~A$350M	~16%	Global Ph3 for solid tumors
New OV (aCF33/others)	~A$200M	~9%	Future virus programs
HER-Vaxx + PD1-Vaxx	~A$50–80M (if any)	~3%	Only if partnered or interest returns
G&A, Manufacturing, IP	~A$200M+	~10%	Manufacturing, expansion, staff, IP defense